R. L. Siegel, K. D. Miller, and A. Jemal, CA: A Cancer Journal for Clinicians, vol.67, pp.7-30, 2017.

F. Maire, J. Cibot, C. Compagne, O. Hentic, P. Hammel et al., Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database, European Journal of Gastroenterology & Hepatology. août, vol.29, issue.8, pp.904-912, 2017.

L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman et al., Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States, Cancer Research. 1 juin, vol.74, issue.11, pp.2913-2934, 2014.

K. S. Scher and A. Hurria, Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress, Journal of Clinical Oncology. 10 juin, vol.30, issue.17, pp.2036-2044, 2012.

L. Talarico, G. Chen, and R. Pazdur, Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration, Journal of Clinical Oncology, vol.22, issue.22, pp.4626-4657, 2004.

T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud et al., FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine. 12 mai, vol.364, pp.1817-1842, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00598658

V. Hoff, D. D. Ervin, T. Arena, F. P. Chiorean, E. G. Infante et al., Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine, New England Journal of Medicine, vol.369, issue.18, pp.1691-703, 2013.

G. Garcia and M. Odaimi, Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review, Journal of Gastrointestinal Cancer. juin, vol.48, issue.2, pp.121-129, 2017.

M. Gilabert, J. L. Raoul, and F. Rousseau, How to treat pancreatic adenocarcinoma in elderly: How far can we, Journal of Geriatric Oncology, vol.8, issue.6, pp.407-419, 2017.

L. Van-der-geest, H. Mohammad, N. Besselink, M. Lemmens, V. Portielje et al., Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer, Cancer Medicine. déc, vol.6, issue.12, pp.2840-2849, 2017.

G. Giordano, M. Pancione, N. Olivieri, P. Parcesepe, M. Velocci et al., Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions, World Journal of Gastroenterology, vol.23, issue.32, p.5875, 2017.

H. A. Burris, M. J. Moore, J. Andersen, M. R. Green, M. L. Rothenberg et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol. juin, vol.15, issue.6, pp.2403-2416, 1997.

O. Hentic, Gemcitabine in elderly patients with advanced pancreatic cancer, World Journal of Gastroenterology, vol.17, issue.30, p.3497, 2011.

C. Neuzillet, J. Bachet, L. Bauguion, C. Durand, L. Conroy et al., , 2018.

M. Charlson, P. Pompei, K. Ales, and C. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, vol.40, issue.5, pp.373-83, 1986.

M. A. Tempero, M. P. Malafa, M. Al-hawary, H. Asbun, A. Bain et al.,

P. Adenocarcinoma, NCCN Clinical Practice Guidelines in Oncology, Journal of the National Comprehensive Cancer Network. août, vol.15, issue.8, pp.1028-61, 2017.

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline

, European Journal of Cancer. janv, vol.45, issue.2, pp.228-275, 2009.

D. Goldstein, R. H. El-maraghi, P. Hammel, V. Heinemann, V. Kunzmann et al., nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial, JNCI Journal of the National Cancer Institute. 31 janv, vol.107, issue.2, p.413, 2015.

G. Giordano, V. Vaccaro, and E. Lucchini, Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): a « real-life » study, J Clin Oncol, 2015.

D. Vita, F. Ventriglia, J. Febbraro, A. Laterza, M. M. Fabozzi et al., NABpaclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice, BMC Cancer, vol.16, issue.1

A. Yu, S. Yasutaka, K. Kenta, S. Takeshi, and H. Kenro, Safety and efficacy of gemcitabine plus nab-paclitaxel therapy in elderly patients with advanced pancreatic cancer, Annals of Oncology, vol.28, 2017.

D. H. Ahn, K. Krishna, M. Blazer, J. Reardon, L. Wei et al., A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis, Ther Adv Med Oncol. févr, vol.9, issue.2, pp.75-82, 2017.

M. Piciucchi, S. Stigliano, L. Archibugi, G. Zerboni, M. Signoretti et al., The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in

, Metastatic Pancreatic Cancer Patients, International Journal of Molecular Sciences. 29 mars, vol.18, issue.4, p.730, 2017.

J. Ventriglia, A. Petrillo, M. Huerta-alváro, M. M. Laterza, B. Savastano et al., Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis, Gastroenterology Research and Practice. 10 juin, vol.2018, pp.1-7, 2018.

M. Vallet-regí, M. Manzano, L. Rodriguez-mañas, C. López, M. Aapro et al., Management of Cancer in the Older Age Person: An Approach to Complex Medical Decisions, The Oncologist. mars, vol.22, issue.3, pp.335-377, 2017.

, NCT02391662: a phase II study of nabpaclitaxel and gemcitabine, in elderly patients with previously untreated, metastatic pancreatic adenocarcinoma, Clinical Trials.gov

J. Betge, J. Chi-kern, N. Schulte, S. Belle, T. Gutting et al., A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/? nab-paclitaxel in elderly pancreatic cancer patients (GrantPax). BMC Cancer [Internet]. déc, vol.18, 2018.

, Un groupe contrôle de patients âgés de 65 à 75 ans a été constitué. Le profil de toxicité, la survie globale (SG) médiane, la survie sans progression (SSP), Méthodes: Etude rétrospective et multicentrique incluant de manière consécutive des patients de plus de 75 ans traités dans 4 hôpitaux français de janvier 2014 à mai 2018

. Résultats, Quarante-deux patients d'âge ? 75 ans (âge médian 78,5) et 85 patients âgés de 65 à 75

, 1) ont été inclus. Les caractéristiques initiales ne différaient pas entre les 2 groupes hormis les patients de moins de 75 ans recevant plus fréquemment la chimiothérapie en 2ème, vol.70

, Le profil de tolérance était similaire. La SG médiane était de 9, vol.82, pp.87-97

, 85) chez les patients de moins de 75 ans. Respectivement, le taux de réponse objectif était de 27% vs. 17%, p=0,24) et la SSP médiane de 5,84 mois, les ? 75 ans et de 6,95 mois (IC95% 5, pp.5-8

. Mots-clés,